CLAIMS

1. A preparation for prevention or treatment of type I diabetes, comprising (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide.

2. The preparation according to claim 1, wherein the component (A) is at least one member selected from the group consisting of proinsulin, insulin B chain, fragments thereof and variants thereof.

3. The preparation according to claim 1 or 2, wherein the component (B) is KRN7000.

4. The preparation according to any one of claims 1 to 3, wherein the component (B) is contained in a liposome.

5. The preparation according to any one of claims 1 to 4, wherein the component (A) and the component (B) are contained in a liposome.

6. The preparation according to any one of claims 1 to 5, wherein the preparation is used for the prevention of type I diabetes.

7. The preparation according to any one of claims 1 to 6, wherein the preparation is administered in the form of subcutaneous or intraperitoneal administration.

8. A method for prevention or treatment of type I diabetes, comprising

administering a therapeutically or prophylactically effective amount of a preparation to a human in need of prevention or treatment of type I diabetes,

wherein the preparation comprises (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide.

9. The method for prevention or treatment according to claim 8, wherein the

component (A) is at least one member selected from the group consisting of proinsulin, insulin B chain, fragments thereof and variants thereof.

10. The method for prevention or treatment according to claim 8 or 9, wherein the component (B) is KRN7000.

11. The method for prevention or treatment according to any one of claims 8 to 10, wherein the component (B) is contained in a liposome.

12. The method for prevention or treatment according to any one of claims 8 to 11, wherein the component (A) and the component (B) are contained in a liposome.

13. The method for prevention or treatment according to any one of claims 8 to 12, wherein the human is a human in need of the prevention of type I diabetes.

14. The method for prevention or treatment according to any one of claims 8 to 13, wherein the preparation is administered in the form of subcutaneous or intraperitoneal administration.

15. Use of a preparation comprising (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide, for the manufacture of an agent for the prevention or treatment of type I diabetes.

CLAIMS

1. A preparation for prevention or treatment of type I diabetes, comprising (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide.

2. The preparation according to claim 1, wherein the component (A) is at least one member selected from the group consisting of proinsulin, insulin B chain, fragments thereof and variants thereof.

3. The preparation according to claim 1 or 2, wherein the component (B) is KRN7000.

4. The preparation according to any one of claims 1 to 3, wherein the component (B) is contained in a liposome.

5. The preparation according to any one of claims 1 to 4, wherein the component (A) and the component (B) are contained in a liposome.

6. The preparation according to any one of claims 1 to 5, wherein the preparation is used for the prevention of type I diabetes.

7. The preparation according to any one of claims 1 to 6, wherein the preparation is administered in the form of subcutaneous or intraperitoneal administration.

8. Use of a preparation comprising (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide, for the manufacture of an agent for the prevention or treatment of type I diabetes.

9. Use according to claim 8, wherein the component (A) is at least one member selected from the group consisting of proinsulin, insulin B chain, fragments thereof and

variants thereof.

10. Use according to claim 8 or 9, wherein the component (B) is KRN7000.

11. Use according to any one of claims 8 to 10, wherein the component (B) is contained in a liposome.

12. Use according to any one of claims 8 to 11, wherein the component (A) and the component (B) are contained in a liposome.

13. Use according to any one of claims 8 to 13, wherein the preparation is administered in the form of subcutaneous or intraperitoneal administration.